07:42 AM EST, 12/10/2025 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) said Wednesday it will collaborate with radiation oncology company Varian to develop applications combining theranostic products and external beam radiation therapy, or EBRT.

Telix said it will explore how its theranostic products can be used more effectively by radiation oncologists to improve selection of patients for EBRT and develop individualized treatment plans.

The collaboration will initially focus on PSMA-PET imaging for prostate cancer radiotherapy patients, Telix said.